UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.19
-0.08 (-0.78%)
Jan 21, 2025, 4:00 PM EST - Market closed
UroGen Pharma Revenue
UroGen Pharma had revenue of $25.20M in the quarter ending September 30, 2024, with 20.87% growth. This brings the company's revenue in the last twelve months to $89.36M, up 15.64% year-over-year. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.
Revenue (ttm)
$89.36M
Revenue Growth
+15.64%
P/S Ratio
4.27
Revenue / Employee
$444,592
Employees
201
Market Cap
430.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
URGN News
- 6 days ago - ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Business Wire
- 6 weeks ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® - Business Wire
- 6 weeks ago - UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
- 7 weeks ago - UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - Business Wire
- 2 months ago - New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® - Business Wire
- 2 months ago - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
- 2 months ago - UroGen Pharma: Choice Based On Near Term High Value PDUFA - Seeking Alpha